IMTHERAPEUTICS
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases. It was founded in 2015 and is headquartered in Aurora, Colorado.
IMTHERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2015-01-01
Address:
Aurora, Colorado, United States
Country:
United States
Website Url:
http://www.imtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
781-235-3060
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Google Apps For Business GoDaddy DNS YouTube COVID-19
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Series A - IMTherapeutics
Morningside Venture Investments
Morningside Venture Investments investment in Series A - IMTherapeutics
Official Site Inspections
http://www.imtherapeutics.com Semrush global rank: 5.89 M Semrush visits lastest month: 1.4 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "IMTherapeutics"
Company Overview - IM Therapeutics
Autoimmune diseases affect about 4% of the world’s population and comprise over 80 different disease conditions. No targeted therapy exists that would allow pre-selection of a patient for …See details»
IMTherapeutics - Crunchbase Company Profile & Funding
Organization. IMTherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. IM Therapeutics develops …See details»
Management Team - IM Therapeutics
Aaron Michels, MD Co-founder, Chief Scientific Officer. Dr. Michels is an Associate Professor of Pediatrics, Medicine, & Immunology at the University of Colorado Denver, the Frieda and George S. Eisenbarth Clinical Immunology …See details»
Contact - IM Therapeutics
Colorado. IM Therapeutics 12635 E. Montview Blvd. Suite 128 Aurora, CO 80045 . IM Therapeutics | ©2019 All Rights Reserved | [email protected] | Terms of ...See details»
IM Therapeutics Company Profile 2024: Valuation, Funding
Nov 13, 2017 Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20220194893-A1: Methods for producing d-alpha-methyldopa: Active: 23-Dec-2020See details»
IM Therapeutics - LinkedIn
IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across ...See details»
Immunomolecular Therapeutics - VentureRadar
Website: https://imtherapeutics.com/ Develops therapeutic designs targeting root cause of autoimmunity, focusing on HLA variants. Platform creates drug molecules for ...See details»
IM Therapeutics Company Profile - Office Locations, Competitors …
IM Therapeutics $10 m in total funding,. See insights on IM Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
IMTherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of ... Money Raised . Lead Investors . Oct 9, 2019: Series A - IMTherapeutics …See details»
IMTherapeutics - Contacts, Employees, Board Members, Advisors …
Organization. IMTherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of …See details»
IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D …
Oct 9, 2019 The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial …See details»
Overview — IM Therapeutics
Affect millions of people for whom ingestion of gluten leads to damage of the small intestineSee details»
IM Therapeutics - Overview, News & Similar companies - ZoomInfo
Jun 24, 2021 Who is IM Therapeutics. IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human …See details»
News and Press - T1D Fund: A Breakthrough T1D Venture
Jul 21, 2021 Learn more at www.IMTherapeutics.com. Contacts. Susan Heins IM Therapeutics [email protected] 864.346.8336. Michele Rozen Rozen Communications …See details»
IM Therapeutics Expands Management Team with David Alleva, …
Apr 6, 2021 Media: Susan Heins IM Therapeutics [email protected] 864-346-8336 Michele Rozen Rozen Communications [email protected] 617-953-2214 …See details»
Overview - IM Therapeutics
Our technology platform screens millions of ‘drug-like’ molecules with sophisticated computational algorithms and 3-D models for their ability to dock within domains of a specific HLA protein.See details»
IM Therapeutics CEO and Key Executive Team | Craft.co
IM Therapeutics's Vice President, R&D is Robert Perni. Other executives include Nandan Padukone, CEO; Peter Gottlieb, Co-Founder, Chief Medical Officer and 3 others. See the full …See details»
Our Approach — IM Therapeutics
HLA gene variants are well known for their role in triggering an autoimmune response in human disease. These HLA molecules such as HLA DQ8 (known for type 1 diabetes and celiac …See details»
News — IM Therapeutics
August 2, 2021. In the News: BioBoss Podcast, CEO Nandan Padukone discusses leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutics …See details»
IM Therapeutics Reports Positive Results in Safety, Tolerability and ...
Jul 21, 2021 Susan Heins IM Therapeutics [email protected] 864.346.8336 Michele Rozen Rozen Communications [email protected] 617.953.2214 Release …See details»